



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.: **09/911,692**Group Art Unit: **1644**Confirmation No.: **8484**Examiner: **R. Schwadron**Filed: **25 July 2001**Applicant: **Darrell R. ANDERSON et al.**For: **Expression and Use of Anti-CD20 Antibodies**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with the requirements and provisions of 37 C.F.R. §§ 1.56, 1.97, and 1.98, applicant cites the documents listed on the Form PTO-1449 that accompanies this paper.

Applicant does not represent that a search has been conducted or that the cited documents, copies of which are submitted with this paper, are prior art against the claims in this application.

Applicant also directs the examiner's attention to the commonly owned, pending U.S. patent applications listed below.

Serial No.	Filing Date	First Inventor
09/783,038	15 Feb 2001	Anderson
09/911,692	25 Jul 2001	Anderson
09/911,703	25 Jul 2001	Anderson
10/096,964	14 Mar 2002	Anderson
10/238,681	11 Sep 2002	Anderson
10/956,039	04 Oct 2004	Anderson

This disclosure statement is filed before the mailing date of a first Office action under the provisions of 37 C.F.R. § 1.97(b)(3). Accordingly, applicant believes that no fee is due. The Director is requested to charge any fee that may be required to make this submission timely or proper to our Deposit Account No. 18-1260.

Respectfully submitted,




David L. Fitzgerald, Reg. No. 47,347
Attorney for Biogen Idec Inc.

SIDLEY AUSTIN BROWN & WOOD LLP
1501 K Street, N.W.
Washington, DC 20005

tel. (202) 736-8818
fax (202) 736-8711

Date: 30 September 2005

INFORMATION DISCLOSURE STATEMENT 	Docket No.	27693-1009	Application No. 09/911,692
	Applicant(s):	ANDERSON, Darrell R.	Examiner: SCHWADRON, Ronald B.
	Filing Date:	7/25/2001	Group Art Unit: 1644

U.S. PATENT DOCUMENTS

Examiner Initial	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	A1	4,975,278	12/4/1990	Senter et al.			
	A2	5,677,180	10/14/1997	Robinson et al.			
	A3	5,686,072	11/11/1997	Uhr et al.			
	A4	5,693,780	12/2/1997	Newman et al.			
	A5	5,721,108	2/24/1998	Robinson et al.			
	A6	5,843,398	12/1/1998	Kaminski et al.			
	A7	6,015,542	1/18/2000	Kaminski et al.			
	A8	6,090,365	7/18/2000	Kaminski et al.			
	A9	6,120,767	9/19/2000	Robinson et al.			
	A10	6,287,537	9/11/2001	Kaminski et al.			
	A11	6,565,827	5/20/2003	Kaminski et al.			
	A12	6,652,852	11/25/2003	Robinson, et al.			
	A13	6,893,625	5/17/2005	Robinson et al.			
	A14	2002-0009444	1/24/2002	Grillo-Lopez			
	A15	2002-0197255	12/26/2002	Anderson et al.			
	A16	2003-0021781	1/30/2003	Anderson et al.			
	A17	2003-0026804	2/24/2003	Grillo-Lopez			
	A18	2003-0082172	5/1/2003	Anderson et al.			
	A19	2003-0147885	8/7/2005	Anderson et al.			
	A20	2003-0206903	11/6/2003	Grillo-Lopez			
	A21	2004-0213784	10/28/2004	Grilo-Lopez et al.			
	A22	2005-0163708	7/28/2005	Robinson et al.			
	A23	2005-0186205	8/25/2005	Anderson et al.			

FOREIGN PATENT DOCUMENTS

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
A24	WO 91/04320	4/4/1991	WO			X
A25	WO 93/02180	2/4/1993	WO			X

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO-A820 (also form PTO-1449) SHEET 1 OF 3	



INFORMATION DISCLOSURE STATEMENT	Docket No. 27693-1009	Application No. 09/911,692
	Applicant(s): ANDERSON, Darrell R.	Examiner: SCHWADRON, Ronald B.
	Filing Date: 7/25/2001	Group Art Unit: 1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

A26	Badger, et al. "Experimental Radioimmunotherapy of Murine Lymphoma with ¹³¹ I-labeled Anti-T-Cell Antibodies." Cancer Research, 46, pp. 6223-6228, 1986.
A27	Buchsbaum, et al. "Improved Delivery of Radiolabeled Anti-B1 Monoclonal Antibody to Raji Lymphoma Xenografts by Predosing with Unlabeled Anti-B1 Monoclonal Antibody." Cancer Research; 52, pp. 637-642, 1992.
A28	Biogen Idec v. Corixa Corporation, Case No. 01-1637-IEG [Doc. Nos. 635, 662, 486] (S.D. California, January 22, 2004).
A29	Chen, et al. "Tumor Idiotype Vaccines. VI. Synergistic Anti-Tumor Effects with Combined "Internal Image" Anti-Idiotypes and Chemotherapy." Journal of Immunology, 143, pp. 1053-1057, No. 3, 1989.
A30	Clark et al. "Role of the Bp35 cell surface polypeptide in human B-cell activation" Vol. 82; pp. 1776-1770, 1985
A31	Clark, et al. "Phase I Evaluation of the Anti-Bp35 Antibody Induces Human B Cell Proliferation: Implications for In Vivo Immunotherapy." Journal Cellular Biochemistry Supp. 9A, p. 63, 1985
A32	DeNardo, et al. "Fractionated Radioimmunotherapy of B-Cell Malignancies with ¹³¹ I-Lym- ⁻¹ ." Cancer Research (Suppl.) 50, pp. 1014s-1016s, 1990.
A33	Idec Pharmaceuticals v. Corixa Corporation, Case No. 01-1637-IEG [Doc. Nos. 486,584] (S.D. California, October 14, 2003).
A34	Kaminski, et al. "Initial Clinical Radioimmunotherapy Results with ¹³¹ I-Anti-B1 (Anti-CD20) in Refractory B-Cell Lymphoma." Antibody Immunoconjugates, and Radiopharmaceuticals Vol. 5, No. 3 p. 345, 1992
A35	Kaminski, et al. "131-I Anti-B1: Initial Clinical Evaluation in B-Cell Lymphoma." Third Conference on Rid and Rit of Cancer, Abstract. No. 144, 1990.
A36	Langmuir, "Radioimmunotherapy: Clinical Results and Dosimetric Considerations." Nuclear Medicine Biology Vol. 19, No. 2, pp. 213-225, 1992.
A37	Levy, et al. "Tumor Therapy with Monoclonal Antibodies." Federation Proceedings 42:9 pp. 2650-2656, 1983
A38	Macklis, et al. "Radiobiologic Sutdies of Low-Dose-Rate ⁹⁰ Y-Lymphoma Therapy." Cancer Supplement, Vol. 73, No. 3, pp. 966-973, 1994.
A39	Maloney, et al. "The Anti-Tumor effect of Monoclonal Anti-CD20 Antibody mAB) Therapy Includes Direct Anti-Proliferative Activity and Production of Apoptosis in CD20 Positive Non-Hodgkin's Lymphoma (NHL) Cell Lines." Interferon and Chronic Myelogenous Leukemia." Fred Hutchinson Cancer Research & University of Washington, 637a, p. 2535

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO-A820 (also form PTO-1449)	
SHEET 2 OF 3	



INFORMATION DISCLOSURE STATEMENT	Docket No. 27693-1009	Application No. 09/911,692
	Applicant(s): ANDERSON, Darrell R.	Examiner: SCHWADRON, Ronald B.
	Filing Date: 7/25/2001	Group Art Unit: 1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

A40	Maloney, et al. "Monoclonal Anti-Idiotype Antibody Therapy of B-Cell Lymphoma: The Addition of a Short Course of Chemotherapy Does Not Interfere with the Antitumor Effect Nor Prevent the Emergence of Idiotype-Negative Variant Cells." Blood, Vol. 80, No. 6, pp. 1502-1510, 1992.
A41	Masucci, et al. "Chemotherapy and Immunotherapy of Colorectal Cancer." Medical Oncology Tumor Pharmacother Vol. 8, No. 3, pp. 207-220, 1991.
A42	Nadler, et al. "A Unique Cell Surface Antigen Identifying Lymphoid Malignancies of B Cell Origin." Journal of Clinical Investigative, Vol. 67, pp. 134-140, 1981.
A43	Reilly, "Radioimmunotherapy of malignancies." Clinical Pharmacy, Vol. 10, pp. 359-375, 1991.
A44	Press, et al. Scientific Proceedings, ASCO, Abstract No. 864, 1986.
A45	See-Lasley, et al. "HODGKIN'S DISEASE AND NON-HODGKIN'S LYMPHOMA Nitrogen mustard, vincristine (Oncovin), procarbazine, and prednisone (MOPP)." Manual of Oncology Therapeutics, C.V. Mosby Company, pp. 44-71, 1981
A46	Senter, et al. "Enhancement of the <i>in vitro</i> and <i>in vivo</i> Antitumor Activities of Phosphorylated Mitomycin C and Etoposide Derivatives by Monoclonal Antibody-Alkaline Phosphatase Conjugates." Cancer Research 49, pp. 5789-5792, 1989.
A47	Stashenko, et al. "Characterization of Human B Lymphocyte-Specific Antigen." The Journal of Immunology Vol. 125, No. 4, pp. 1678-1685, 1960.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO-A820 (also form PTO-1449)	SHEET 3 OF 3